Micro/Nanostructured Materials and Microfluidic Diagnostic Platforms Enable Multimodal Detection of Circulating Tumor Cells
Exploration · 2026-10 · 6 (5)
DOI: 10.1002/exp2.70239 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Exploration, online erschienen am 11.10.2026. Verfasst von Hao Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology the First Affiliated Hospital of Soochow University Suzhou China. Die Arbeit nennt 184 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Postdoctoral Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Circulating tumor cells (CTCs), as pivotal targets in liquid biopsy, offer dynamic, multidimensional insights into tumor heterogeneity and metastatic progression. However, their extreme rarity, pronounced heterogeneity, and the complexity of the blood microenvironment severely constrain detection accuracy. Advances in micro/nanomaterials and functional device engineering have enabled substantial improvements in CTC enrichment efficiency by refining the topographical and chemical properties of capture interfaces. These innovations also provide a compatible foundation for multimodal molecular profiling. This review systematically outlines the structure–function relationships of functionalized nanomaterials, microfiltration substrates, and biomimetic microfluidic devices, highlighting how material parameters—such as nanoscale architectures and membrane pore sizes—govern CTC capture performance. We further explore the integration of micro/nanomaterials with functional platforms for multidimensional molecular analyses across DNA, RNA, and protein levels. Coupled with emerging digital PCR technologies, these systems show promise in overcoming the sensitivity barriers associated with rare mutation detection and protein quantification, enabling multi‐omics data fusion. We also discuss how artificial intelligence (AI)‐driven feature selection, clustering, and prediction integrate multidimensional data to decode tumor heterogeneity and guide disease monitoring. Despite rapid progress, key challenges remain—including the lack of standardization, limited integration of multi‐omic datasets, and the need for robust clinical validation. Future directions may lie in the convergence of microfluidic‐integrated materials, single‐cell multi‐omics, and AI‐driven analytics to establish dynamic, high‐resolution monitoring platforms that bridge the gap between fundamental research and clinical precision oncology.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology the First Affiliated Hospital of Soochow University Suzhou China.
- Suzhou Institute of Biomedical Engineering and Technology Chinese Academy of Sciences Suzhou China.
- State Key Laboratory on Technologies for Chinese Medicine Pharmaceutical Process Control and Intelligent Manufacture Nanjing University of Chinese Medicine Nanjing China.
- School of Electrical and Electronic Engineering Nanyang Technological University Singapore Singapore.
Förderung
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Li, H., Sun, J., Liu, K., Wang, S., Fu, B., Zhu, H., Cao, P., & Han, X. (2026). Micro/Nanostructured Materials and Microfluidic Diagnostic Platforms Enable Multimodal Detection of Circulating Tumor Cells. Exploration, 6(5). https://doi.org/10.1002/exp2.70239
Vancouver
Li H, Sun J, Liu K, Wang S, Fu B, Zhu H, et al. Micro/Nanostructured Materials and Microfluidic Diagnostic Platforms Enable Multimodal Detection of Circulating Tumor Cells. Exploration. 2026;6(5). doi:10.1002/exp2.70239
BibTeX
@article{Li2026,
author = {Li, Hao and Sun, Jiaojiao and Liu, Kunguo and Wang, Shijie and Fu, Bowen and Zhu, Hong and Cao, Peng and Han, Xin},
title = {Micro/Nanostructured Materials and Microfluidic Diagnostic Platforms Enable Multimodal Detection of Circulating Tumor Cells},
journal = {Exploration},
year = {2026},
volume = {6},
number = {5},
doi = {10.1002/exp2.70239}
}
EUVIMED